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Abstract: Owing to the high prevalence and associated complications of liver fibrosis, of any etiology,
and nonalcoholic fatty liver disease (NAFLD), both have become important public health issues. Liver
biopsy is considered the gold standard for diagnosis and staging of liver fibrosis, as well as NAFLD.
Recent studies have discovered and validated several non-invasive biochemical biomarkers and imaging
procedures for the diagnostics of liver fibrosis and NAFLD. In comparison to patented tests (FibroTest®,
Fibrometer®, and Hepascore®), non-patented tests (APRI, ELFG, FIB-4, Forns Index, and MP3) tend to
have a lower diagnostic performance, especially for the diagnosis of significant fibrosis (METAVIR stage
F2). The difference in performance is less pronounced for the diagnosis of cirrhosis (METAVIR stage F4).
Elastography is superior to biomarkers in the diagnosis of cirrhosis (F4) but not fibrosis (F2). However, in
20% of patients elastography cannot be performed or evaluated due to anatomical reasons. Cytokeratin
18 (CK-18) is the most promising single biomarker for the diagnosis of non-alcoholic steatohepatitis
(NASH). Scores and algorithms have been less extensively validated for their diagnostic performance in
diagnosing and staging of NAFLD and NASH as compared with fibrosis in chronic hepatitis. Data are
promising. Patented scores as well as CK-18 appear slightly superior to freely available scores including
the NAFLD fibrosis score, which is recommended by American guidelines. In conclusion, non-invasive
biomarkers and elastography appear promising as prescreening tools to limit the number of liver biopsies.
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 Laboratory diagnostics of non-alcoholic fatty liver 
disease 
 Abstract: Owing to the high prevalence and associated 
complications of liver fibrosis, of any etiology, and non-
alcoholic fatty liver disease (NAFLD), both have become 
important public health issues. Liver biopsy is consid-
ered the gold standard for diagnosis and staging of liver 
fibrosis, as well as NAFLD. Recent studies have discov-
ered and validated several non-invasive biochemical bio-
markers and imaging procedures for the diagnostics of 
liver fibrosis and NAFLD. In comparison to patented tests 
(FibroTest  ®  , Fibrometer  ®  , and Hepascore  ®  ), non-patented 
tests (APRI, ELFG, FIB-4, Forns Index, and MP3) tend to 
have a lower diagnostic performance, especially for the 
diagnosis of significant fibrosis (METAVIR stage F2). The 
difference in performance is less pronounced for the diag-
nosis of cirrhosis (METAVIR stage F4). Elastography is 
superior to biomarkers in the diagnosis of cirrhosis (F4) 
but not fibrosis (F2). However, in 20% of patients elastog-
raphy cannot be performed or evaluated due to anatomi-
cal reasons. Cytokeratin 18 (CK-18) is the most promising 
single biomarker for the diagnosis of non-alcoholic stea-
tohepatitis (NASH). Scores and algorithms have been less 
extensively validated for their diagnostic performance in 
diagnosing and staging of NAFLD and NASH as compared 
with fibrosis in chronic hepatitis. Data are promising. 
Patented scores as well as CK-18 appear slightly superior 
to freely available scores including the NAFLD fibrosis 
score, which is recommended by American guidelines. In 
conclusion, non-invasive biomarkers and elastography 
appear promising as prescreening tools to limit the num-
ber of liver biopsies. 
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 Introduction 
 Liver diseases are characterized by four basic patho-
mechanisms, three of which are captured by traditional 
clinical laboratory parameters: necrosis, cholestasis and 
metabolic insufficiency. Fibrosis and its most pronounced 
form, cirrhosis, however, have been impenetrable to non-
invasive diagnostics for a long time. With the advancement 
of therapeutic options, the need for reliable diagnostics of 
liver fibrosis has increased massively. However, it is dif-
ficult to develop biomarkers for the noninvasive staging 
of liver fibrosis, because it is a component of the normal 
healing process after injury, infection, and many other 
etiological factors. For decades, liver biopsy has been the 
gold standard for the diagnosis and staging of liver fibro-
sis, especially since it also allows for the assessment of 
necrosis, inflammatory activity, and deposits of fat (stea-
tosis), iron or copper. In recent years, a number of indirect 
methods based on laboratory parameters and/or imaging 
procedures have been developed and validated, but they 
have been incorporated into clinical practice to varying 
degrees internationally. The noninvasive methods appear 
particularly suitable for pre-screening in order to limit the 
number of liver biopsies  [1 – 4] . 
 The gold standard  – liver biopsy 
 Although considered the gold standard, liver biopsy 
is subject to significant disadvantages such as limited 
access, high cost and risk for the patient. Among the 
complications, pain (85%) and hypotension are the most 
common; intraperitoneal bleeding (approximately 0.2%) 
and injury the most severe. The risk of hospitalization 
after a liver biopsy is 1% – 5%; the mortality approximately 
0.01%. Due to fear of these complications, many patients 
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avoid having a liver biopsy performed. In addition, the 
quality of a liver biopsy is limited by errors in sample col-
lection and assessment (inaccuracy) as well as reproduc-
ibility (high intra- and inter-observer variability)  [4] . 
 The most commonly used methods for the semiquan-
titative scoring of the fibrosis degree are the Ishak and 
the Metavir scores, which were originally developed to 
assess chronic hepatitis, and the Brunt score, which was 
developed for the assessment of non-alcoholic fatty liver 
disease ( Table 1 ). The most important, quality-limiting 
factor of these standardized methods is the collection of 
samples, which causes unreliable staging classifications 
or, among different pathologists, discrepant staging clas-
sifications in one third of the cases. Accordingly, biopsies 
should be at least 20 – 25 mm and/or have at least 11 portal 
tracts. Unfortunately, this requirement is met only by 
approximately half of the biopsies. Another limitation is 
the non-linear relationship between the degree of fibro-
sis and clinical relevance. Thus, the F0 → F1 transition is 
clinically less relevant than the F2 → F3 transition. For cir-
rhosis (F4), there is no sub-differentiation of severity  [4] . 
Taken together, these limitations demonstrate that the 
gold standard of liver biopsy is not ideal. 
 Noninvasive methods have several fundamental 
advantages over liver biopsies. By comparison, they are 
virtually free of side effects, easier to control in pre-analyt-
ical terms, more objective because they are less dependent 
on the tester, easily repeatable and more cost-effective. 
However, they match histology only to a limited extent. 
Furthermore, they are strongly influenced by the specific 
etiology of the underlying liver disease and other clinical 
conditions of the patient (e.g., medication). 
 The limited quality and reliability of the gold 
standard of liver biopsy means that, in comparative 
cross-sectional studies, biomarkers are by definition 
inferior to a liver biopsy in terms of diagnostic signifi-
cance. This dilemma can only be resolved by longitu-
dinal studies in which the predictive values of biopsies 
and biomarkers are compared with respect to clinical 
endpoints, such as death, portal hypertension or pro-
gression/regression of fibrosis in response to alcohol 
abstinence, virostatic therapy for hepatitis B and C or an 
improved metabolic situation in connection with non-
alcoholic steatohepatitis (NASH). 
 Biomarkers that are measurable in 
the blood 
 In recent years a number of potential biomarkers of liver 
fibrosis have been discovered and evaluated in what often 
amounted to small-scale studies. In principle, the blood 
markers can be divided into direct and indirect markers: 
direct markers are molecules which are released from the 
extracellular matrix, or from stellate cells, e.g., hyal uronic 
acid or  α 2-macroglobulin. Indirect markers are mole-
cules that reflect the response of the liver parenchyma 
to fibrosis: cell death (ALT), cholestasis (bilirubin,  γ GT), 
metabolic insufficiency (INR), and portal hypertension 
(thrombocytopenia, hypergammaglobulinemia). Direct 
markers detect the fibrosis at earlier stages, but are less 
specific, because they are also formed in non-hepatic 
fibrosis. Therefore, direct and indirect markers are fre-
quently combined.  Table 2 summarizes the best validated 
marker combinations. 
 The diagnostic quality of simple clinical or laboratory 
findings, independent of etiology, has been examined in 
 Table 1   Semi-quantitative histological methods for assessing liver fibrosis  [4] .  
Chronic hepatitis B or C  
 
NAFLD 
METAVIR   Ishak Brunt 
F0  =  no fibrosis   F0  =  no fibrosis   F0  =  no fibrosis
F1  =  expanded portal fibrosis  F1  =  fibrous expansion of some portal areas, with or without fibrous 
septa
  F1A  =  mild perisinusoidal fibrosis
F2  =  periportal fibrosis with 
formation of few septa
  F1  =  fibrous expansion of most portal areas, with or without fibrous 
septa
  F1B  =  moderate perisinusoidal 
fibrosis
F3  =  extensive bridging   F3  =  fibrous expansion of most portal areas with occasional portal-
portal bridging
  F1C  =  exclusive portal/periportal 
fibrosis
F4  =  cirrhosis   F4  =  fibrous expansion of most portal areas with extensive portal-
portal and portal-central bridging
  F2  =  both perisinusoidal and 
portal/periportal fibrosis
  F5  =  extensive bridging with occasional nodes (incomplete cirrhosis)   F3  =  Bridging fibrosis
   F6  =  cirrhosis   F4  =  cirrhosis 
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a large meta-analysis of 86 studies that were qualified 
by the authors as appropriate and that verified liver cir-
rhosis by means of biopsies  [6] . A total of 19,533 patients 
were included in the meta-analysis, of whom 4725 suf-
fered from cirrhosis diagnosed by biopsies (prevalence: 
24%; 95% CI, 20% – 28%). Several findings of physical 
examinations or simple laboratory tests increase the 
probability of cirrhosis, that is, the existence of an 
ascites (likelihood ratio LR = 7.2, 95% CI: 2.9 – 12), a plate-
let count  < 160 × 10 3 / μ L, (LR = 6.3, 95% CI: 4.3 – 8.3), spider 
angiomas (LR = 4.3, 95% CI: 2.4 – 6.2) or the combination of 
simple laboratory test results, such as a Bonacini cirrhosis 
discriminant score  > 7 (LR = 9.4, 95% CI: 2.6 – 37) or an APRI 
index  > 2 (LR = 4.6, 95% CI: 3.2 – 6.0). For ruling out cirrho-
sis, a Lok index  < 0.2 (LR = 0.09, 95% CI: 0.03 – 0.31), a plate-
let count  < 160 × 10 3 / μ L, (LR = 0.29, 95% CI: 0.20 – 0.39) and 
the absence of hepatomegaly (LR = 0.37, 95% CI:  0.24 – 0.51) 
have proved to be the most appropriate characteristics. 
In total, a physician ’ s overall clinical impression was 
less informative than the individual or combined medical 
laboratory findings, particularly in connection with ruling 
out cirrhosis (positive LR = 4.8, 95% CI, 2.5 – 7.2; negative 
LR = 0.52, 95% CI, 0.33 – 0.71)  [6] . 
 The biomarkers and the thereof derived algorithms 
were evaluated particularly for patients with hepatitis B or 
C, as well as patients with non-alcoholic fatty liver disease 
(NAFLD). The monitoring of liver disease in patients with 
hepatitis B or C is important in order to determine the 
prognosis and indicate antiviral therapies. Overall, the 
biomarkers are more reliable in the detection of cirrhosis 
than in the detection of intermediate fibrosis stages  [1 – 5] . 
The most frequently validated tests are APRI (a free, non-
patented algorithm that combines the measured variables 
AST and platelet count) and FibroTest  ®  (a patented test, 
which is common in France and comprises the measured 
variables  γ GT, haptoglobin, bilirubin, apolipoprotein AI 
and  α 2-macroglobulin). 
 A meta-analysis of the results of the APRI test on 6259 
HCV patients from 33 studies found mean AUROC values 
of 0.77, and 0.83 for the detection of significant fibrosis 
or cirrhosis  [7] . A meta-analysis of the FibroTest  ®  test on 
3501 patients infected with the hepatitis C virus [HCV], 
and 1457 patients infected with the hepatitis B virus [HBV] 
 [8] found a standardized AUROC of 0.84 for the diagnosis 
of significant fibrosis, without any significant difference 
between HCV (AUROC = 0.85) and HBV (AUROC = 0.80). The 
proportion of discordant results between the biopsy and 
FibroTest  ®  is about 25%. As set forth above, the diagnostic 
quality of the biomarkers is also limited by the pre-analyt-
ical and analytical errors of the biopsy. The developer and 
provider of FibroTest  ®  estimates that the discordant results 
are caused by biopsy errors and errors of the biomarker test 
in equal parts. They developed, therefore, the concept of 
 “ risk of false-positive and false-negative results ” (RFPFN) 
and evaluated their database of nearly 370,000 measure-
ment results  [9] . In the general population, the RFPN was 
0.5% – 1%. It increased to 2% and more in high-risk groups, 
such as patients from tertiary care centers or HIV centers 
or in Africans of sub-Saharan origin. Among the laboratory 
parameters, a low concentration of haptoglobin (0.46%) 
and a high concentration of apoA-I (0.2%) contributed the 
most to the RFPFN. Overall, the authors concluded from 
their data that FibroTest  ®  could be applied to 99% of all 
patients and 97% of high-risk patients. 
 In a direct comparison study of 913 HCV and 284 HBV 
patients, the diagnostic qualities of the three patented 
 Table 2   Combinations of serum biomarkers for the diagnosis of liver fibrosis  [5, 6] .  
Score   Components 
APRI   AST/platelet ratio
Forn ’ s index  Age, platelets,  γ GT, cholesterol
Bonacini   Platelets, AST, ALT, INR
GUCI   AST, INR, platelets
HALT C   Hyaluronic acid, TIMP1, platelets
LOK index   AST, ALT, INR, platelets
MP3   TIMP1, P3NP
ViraHep   Race, age, AST, platelets, alkal. phosphatase
FIB-4   AST, ALT, platelets
ELF plus  ®    Hyaluronic acid, TIMP1, P3NP, BMI, diabetes mellitus type 2/impaired fasting glucose, AST, ALT, platelets, albumin
Fibrometer  ®    Age, weight, fasting plasma glucose, AST, ALT, ferritin, platelets
FibroSpect  ®     α 2-macroglobulin, hyaluronate, TIMP1
FibroTest  ®     α 2-macroglobulin, apolipoprotein AI, haptoglobin, bilirubin,  γ GT, ALT
HepaScore  ®    Age, sex,  α 2-macroglobulin, hyaluronate, TIMP1,  γ GT, 
 TIMP1, tissue inhibitor of metalloproteinase 1; P3NP, aminoterminal peptide of procollagen III. 
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tests (FibroTest  ®  , Fibrometer  ®  and Hepascore  ®  ) and the 
non-patented APRI test did not differ. The AUROC values 
ranged between 0.72 and 0.78 for significant fibrosis, and 
between 0.77 and 0.86 for cirrhosis  [10] . In another com-
parative study of nine biomarker tests on 436 patients 
with hepatitis C, the AUROC values in connection with 
detecting significant fibrosis (F>2) were 0.75 – 0.78 for non-
patented tests (hyaluronic acid, Forn ’ s index, APRI, MP3, 
FIB-4, ELFG) and 0.80 – 0.82 for patented tests (FibroTest  ®  , 
Fibrometer  ®  , Hepascore  ®  ). For the detection of cirrhosis, 
the corresponding AUROC ranges were 0.83 – 0.88 and 
0.86 – 0.89  [11] . 
 Almost all models for assessing the quality of clini-
cal or histological methods for assessing the severity 
of fibrosis are based on baseline clinical, laboratory or 
pathology findings. Since the severity and the clinical and 
laboratory surrogates of liver disease change over time, 
dynamic models should yield a better prognostic value. 
With this hypothesis, two models were developed from 
the data of the Hepatitis C Long-Term Treatment Against 
Cirrhosis (HALT-C) study to predict clinical decompensa-
tion (model 1) and/or liver transplantation or hepatogenic 
death (model 2)  [12] . In 470 patients, an algorithm of plate-
let count, AST/ALT ratio, bilirubin at baseline, as well as 
at times of major changes in platelet count and bilirubin 
and albumin levels, yielded the best prediction of clinical 
decompensation in 60 patients (model 1). In 483 patients, 
an algorithm of platelet count and albumin concentration 
at baseline, as well as the deterioration of the AST/ALT 
ratio and the decrease in the albumin level were the best 
predictors of 79 transplantations or liver-related deaths 
(model 2)  [12] . 
 Imaging methods 
 The activation of hepatic stellate cells and the formation of 
the extracellular matrix lead to changes in the microstruc-
ture of the liver, which manifest themselves in decreas-
ing elasticity and altered blood flow  [1 – 4] . The changes 
in elasticity can be measured noninvasively by means of 
sonographic elastography (FibroScan ™ ), magnetic reso-
nance imaging (MR) or acoustic radiation force impulse 
(ARFI). 
 In the case of ultrasound-based transient elastography 
(Fibroscan ™ ), the elasticity of the hepatic parenchyma 
is measured by 5  MHz ultrasound, and the initiation of 
low-frequency elastic waves by means of a special ultra-
sonic vibrator. The propagation speed of the pulse-echo 
waves is measured by means of ultrasound imaging. Since 
fibrotic tissue is harder than healthy liver parenchyma, 
the propagation speed correlates with the degree of fibro-
sis. FibroScan ™ has been approved in Europe for clini-
cal diagnosis. The method has been evaluated for various 
liver diseases, such as hepatitis B and C, alcoholic liver 
disease and NAFLD. Meta-analyses demonstrated the 
reliability of Fibroscan ™ for the diagnosis of significant 
fibrosis (F2, AUC = 0.84), severe fibrosis (F3, AUC = 0.89), 
and cirrhosis (F4, AUC = 0.94). However, the AUC in F2 
varied greatly depending on the underlying disease. In the 
diagnosis of cirrhosis, the FibroScan technology is limited 
by necrotic activity and inflammation in NAFLD patients. 
Other quality-limiting factors are the expertise of the phy-
sician, the patient ’ s age, the presence of ascites, a body 
mass index   ≥  28 kg/m 2 and abdominal obesity, as well as 
the width of the intercostal spaces. Thus, a large study did 
not yield any results in 20% of the cases studied  [2] . 
 ARFI combines conventional ultrasound with a 
local examination of liver elasticity. Overall, the results 
of FibroScan ™ and ARFI correlate well. In comparison 
with FibroScan ™ , the limiting influence of anatomical 
obstacles (e.g., large vessels) or steatosis is minimized for 
ARFI. Another advantage is the possible integration of 
the ARFI software with conventional ultrasound devices, 
thus eliminating the need for the expensive investment of 
Fibro Scan ™  [2] . 
 Liver elasticity and changes in water diffusion, which 
occur in connection with cirrhosis, can be measured by 
MRI. In magnetic resonance elastography (MRE), the 
acoustic shear waves propagating through the liver tissue 
are visualized and quantified directly in three steps: 1) 
Generation of mechanical waves in the tissue; 2) Imaging 
of micron level displacements caused by the propagat-
ing waves by means of a special MRI technique (oscillat-
ing motion-sensitizing gradients); and 3) Processing the 
wave images using an algorithm that creates quantitative 
maps of the physical properties of the liver. This is how 
MRE represents the distribution of connective tissue in 
the liver. Compared to biopsies, MRE shows a very good 
match regarding the detection of fibrosis degree: in con-
trast to FibroScan ™ , MRE is characterized by the fact that 
it can capture even the lowest fibrosis degree and that the 
failure rate is smaller: 94%, instead of 84%, of the tests 
can be performed. Only very severely obese patients who 
do not fit into the MRI machine are an obstacle  [2] . 
 In the ANRS HCEP23 study, the diagnostic value of 
transient elastography (FibroScan ™ ) and nine blood 
biomarkers was compared in almost 500 patients with 
chronic hepatitis C: Fibrometer  ®  , FibroTest  ®  , Forns index, 
APRI, MP3, ELFG, Hepascore  ®  , Fib4 and hyaluronic acid. 
The elastography could not be evaluated for 22% of the 
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patients, therefore all methods were compared for 382 
patients  [11] . As for the diagnosis of significant fibrosis, 
FibroScan  ®  with an AUROC of 0.82 was not superior to the 
patented biomarkers (0.81 for FibroTest  ®  , 0.82 for Hepas-
core  ®  and 0.83 for Fibrometer  ®  ), but it was superior to 
the clinical scores (0.74 – 0.78). Elastography performed 
better than the biomarkers in the detection of cirrhosis 
[AUROC = 0.93 vs. 0.84 (Fib4) to 0.90 (Fibrometer  ®  )]. The 
authors also calculated the number of biopsies to be 
avoided by the use of imaging or biomarkers, using as 
the default the 90% cut-off values for negative and posi-
tive predictive values. The differences between Fibrom-
eter  ®  (36.6%), Fibrotest  ®  (35.6%), Hepascore  ®  (30.5%) and 
FibroScan (45.8%) were not statistically significant  [11] . 
 The non-optimal diagnosis of significant fibrosis by 
both biomarkers and imaging suggests that the two strate-
gies should be combined. In fact, this concept has already 
been tested in initial studies. In the above-described 
study of Zarski et  al., the combination of elastography 
and patented biomarkers increased the proportion of 
correctly classified patients with significant fibrosis (F2) 
from  70% – 73% to 80% – 83%  [11] . In another study involv-
ing patients with chronic hepatitis C, 97% of patients 
were correctly classified by a combination algorithm of 
FibroTest  ®  and APRI  – theoretically 48% of biopsies could 
have been avoided. The combination of elastography and 
Fibrotest would have helped to avoid as many as 79% of 
biopsies  [13] . Similar results were found for the combina-
tion of elastography and Fibrometer  ®   [14] . 
 These promising results for the noninvasive diagnosis 
of fibrosis are reflected in the most recent recommenda-
tions of the  European Association for the Study of Liver Dis-
eases on Chronic Hepatitis C, which recommend the use 
of noninvasive methods for the diagnosis and monitor-
ing of fibrosis in connection with chronic hepatitis C  [15] . 
 Figure  1 illustrates a clinical path for implementing this 
concept. 
 Definitions and epidemiology of 
non-alcoholic fatty liver disease 
(NAFLD) 
 The diagnosis of NAFLD requires firstly the detection of 
steatosis by means of histology or imaging, and secondly 
the exclusion of causes of secondary fatty liver such as 
excessive drinking, the taking of steatogenic drugs or 
hereditary storage diseases ( Table 3 ). NAFLD is divided 
histologically into NAFL (non-alcoholic steatosis or fatty 
liver) and NASH (non-alcoholic steatohepatitis or fatty 
liver hepatitis) ( Table 4 )  [16] . 
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 Figure 1   Proposal of a clinical path for the use of noninvasive methods for risk and treatment stratification of chronic hepatitis C. 
 F0 – F4  = Metavir stages of fibrosis, I0 – I6  = Ishak stages of fibrosis. Modified from reference  [3] . 
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 Frequently, patients with NAFLD are overweight or 
obese, or suffer from diabetes mellitus and dyslipidemia 
characterized by hypertriglyceridemia and low HDL cho-
lesterol. Accordingly, NAFLD today is considered the 
hepatic manifestation of the metabolic syndrome. NAFLD 
occurs frequently with other diseases and symptoms 
associated with the metabolic syndrome, e.g., polycystic 
ovary syndrome, sleep apnea syndrome and male hypo-
gonadism  [16] . The diagnosis is clinically relevant, given 
the increased risk, due to NAFLD, of the manifestation of 
diabetes, coronary heart disease, chronic kidney disease, 
as well as given the progression of NAFLD to cirrhosis and, 
eventually, liver cancer  [16 – 19] . 
 A diagnosis of NAFLD is becoming increasingly 
common with the rising prevalence of obesity and the 
metabolic syndrome. In many countries, NAFLD is con-
sidered the most common cause of elevated liver enzyme 
activities in plasma. However, the epidemiologically docu-
mented prevalence of NAFLD varies significantly, depend-
ing on the diagnostic methods and criteria used, between 
 Table 3   Causes of secondary steatosis  [16] . 
Macrovesicular steatosis 
   –  Excessive alcohol consumption
   –  Hepatitis C (genotype 3)
   –  Wilson ’ s disease
   –  Lipodystrophy
   –  Starvation
   –  Parenteral nutrition
   –  Abetalipoproteinemia
   –  Medication (e.g., amiodarone, methotrexate, tamoxifen, 
corticosteroids)
Microvesicular steatosis
   –  Reye syndrome
   –  Medication (valproate, anti-retroviral drugs)
   –  Acute fatty liver of pregnancy
   –  HELLP syndrome
   –  Congenital metabolic diseases (e.g., LCAT deficiency, 
cholesteryl ester storage disease/Wolman disease) 
 Table 4   Staging of non-alcoholic fatty liver disease (NAFLD)  [16] . 
 – Non-alcoholic fatty liver disease (NAFLD): 
   Umbrella term for all manifestations (steatosis  = NAFL), 
steatohepatitis (NASH), fibrosis, cirrhosis
 –  Non-alcoholic fatty liver (steatosis  = NAFL):
   Fatty liver with no evidence of liver cell necrosis (ballooning) or 
fibrosis (bridging): Low risk for cirrhosis or liver failure
 –  Non-alcoholic fatty liver hepatitis (steatohepatitis  = NASH):
   Fatty liver with signs of inflammation: Liver cell necrosis 
(ballooning) and/or fibrosis (bridging): Increased risk for cirrhosis 
or liver failure. Hepatocellular carcinoma rather rare 
3% and 50%. In two histology studies of live liver donors, 
the prevalence was 20% and 51%, respectively  [20, 21] . A 
Texas population study of middle-aged people that meas-
ured the liver fat by magnetic resonance spectroscopy, but 
ignored patients ’ alcohol history, showed a prevalence 
of 31%  [22] . In another American study  [23] , which cap-
tured steatosis sonographically and took alcohol history 
into account, the prevalence of NAFLD was 46%, of whom 
almost 30% had NASH (12.2% overall prevalence). In the 
National Health and Nutrition Examination Survey III 
(NHANES III), which was conducted between 1988 and 
1994, the prevalence of NAFLD among 11,613 subjects 
was almost 19% (sonographic steatosis with exclusion of 
chronic alcohol consumption as well as hepatitis B and 
C). Almost 12% of NAFLD patients, or more than 2% of the 
total population, had NASH  [24] . Within the total popu-
lation, NAFLD is associated with sex, age and ethnicity: 
men are affected more often than women; the probability 
of advanced stages (NASH, cirrhosis) increases with age, 
overweight/obesity and the presence of hypertension  [24] ; 
and Hispanic whites are affected more often than non-
Hispanic whites, who in turn are affected more frequently 
than Africans or Native Americans  [16, 24] . 
 The prevalence of NAFLD in at-risk groups is even 
higher than in the general population. In NHANES III, 
the prevalence of NAFLD in 7156 overweight or obese 
individuals was 27.8%, compared to 7.4% among 4457 
normal-weight subjects. It is interesting to note that the 
independent NAFLD predictors differed for the normal-
weight and the overweight: they are younger and more 
often female and exhibit fewer components of the meta-
bolic syndrome  [24] . More than 90% of massively obese 
patients who undergo bariatric surgery have NAFLD. Up 
to 5% suffer from cirrhosis, which is often unknown prior 
to surgery  [16] . In patients with type 2 diabetes mellitus 
(T2DM), the prevalence fluctuates between 69% and 87% 
 [16] . In pre-diabetic patients with impaired fasting plasma 
glucose or glucose intolerance, the prevalence of NAFLD 
is already increased  [17, 18] . In lipid-clinic patients, the 
NAFLD prevalence is 50%. 
 Practical recommendations on the 
diagnostics and management of 
NAFLD 
 The American Gastroenterological Association, the 
 American Association for the Study of Liver Diseases 
and the American College of Gastroenterology published 
joint practical recommendations on the diagnosis and 
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management of NAFLD in 2012  [16] . A position paper 
by the European Society for Pediatric Gastroenterology, 
Hepatology, and Nutrition (ESPGHN) dealt with NAFLD in 
childhood and adolescence  [24, 25] . 
 As is common today, and recommended by the AASLD 
Practice Guidelines Committee, the total of 45 practical 
recommendations of the American gastroenterologists 
and hepatologists are classified according to GRADE 
 (Grading  of Recommendation Assessment, Development, 
and Evaluation) , as strong (1) or weak (2). In addition, the 
recommendations are weighted according to the quality of 
their evidence: high (A), moderate (B) and low (C). Below, 
only the recommendations relevant to the diagnostics 
have been summarized  [16] . The numbers and letters in 
parentheses refer to the GRADE classification or quality of 
evidence, as described above.
 –  In investigating cases of suspected NAFLD, it is essen-
tial to exclude other causes of fatty liver disease and 
co-existing liver diseases (1A). 
 –  Patients with unexpected findings of steatosis 
obtained through imaging that also exhibit clini-
cal or laboratory evidence of liver disease should be 
subjected to differential diagnosis for clarification 
(1A). In order to differentiate between alcoholic and 
non-alcoholic liver disease, an average consumption 
of  > 21 drinks/week for men and  > 14 drinks/week for 
women is defined (2C ). In the case of persistently high 
ferritin levels and pathological transferrin saturation, 
hemochromatosis (HFE 282Y homozygosity) should 
be ruled out genetically or through biopsy (1B). In the 
presence of auto-antibodies or other indications of 
autoimmune hepatitis (very high ALT activity, strong 
 γ –globulin increase), all tests should be performed 
consistently to rule out autoimmune hepatitis (1B). 
 –  Patients with unexpected findings of steatosis 
obtained by imaging that exhibit no clinical or labo-
ratory evidence of liver disease should have their 
condition clarified in relation to metabolic risk fac-
tors (overweight, obesity, diabetes and glucose intol-
erance, dyslipidemia) and secondary causes of fatty 
liver (alcohol, drugs) (1A). For them, no liver biopsy 
should be performed (1B). 
 –  As for adult patients in primary care or in diabetes and 
obesity clinics, screening for NAFLD is currently not 
recommended, because the long-term benefits and 
cost-effectiveness are unknown (1B). For the same 
reasons, a systematic screening of family members for 
NAFLD is not recommended (1B). 
 –  The NAFLD Fibrosis Score ( www.nafldscore.com ) is 
helpful in identifying NAFLD patients with severe 
fibrosis (bridging) or cirrhosis (1B). The plasma 
concentration of cytokeratin 18 fragments (CK-18) is a 
promising biomarker for the identification of patients 
with NASH or advanced fibrosis. Nevertheless, it is 
too early to recommend the marker for clinical rou-
tine (1B). 
 –  The presence of a metabolic syndrome increases the 
probability of steatohepatitis in NAFLD patients. 
Accordingly, a biopsy is to be considered (1B). The 
presence of a metabolic syndrome and high NAFLD 
fibrosis score can be used for the identification of 
patients at high risk of NASH or advanced fibrosis 
(1B). Liver biopsies should be considered for NAFLD 
patients with an increased risk of NASH or advanced 
fibrosis (1B). Liver biopsies should also be considered 
for patients with suspected NAFLD, in cases where 
competing causes cannot be ruled out without a liver 
biopsy (1B). 
 –  Patients with NASH/cirrhosis should be screened for 
esophageal varices (1B). Patients with NASH/cirrho-
sis should be monitored for the development of liver 
cancer (1B). Routine repetition of liver biopsies are not 
recommended for patients with NAFL or NASH (2C). 
 –  Apart from the causes to be clarified in adults, in 
non-overweight children with fatty liver, monogenic 
causes should also be examined, that is, disorders of 
fatty acid oxidation, lysosomal storage diseases and 
peroxisomal disorders (2C). Low auto-antibody titers 
are commonly found in children with NAFLD. High 
titers, especially in combination with marked eleva-
tions of ALT and  γ –globulin, should give rise to a liver 
biopsy to rule out autoimmune hepatitis (2B). A sys-
tematic screening for NAFLD in overweight or obese 
children is not recommended as there is no evidence 
of any benefit. This is in contrast to another expert 
committee, which recommended a biennial screening 
of liver enzymes (1B). In children, a liver biopsy is rec-
ommended if the diagnosis is uncertain, if multiple 
diagnoses seem possible or before potentially hepa-
totoxic medication is administered (1B)  [25] . In chil-
dren, a biopsy is recommended also before the start 
of any drug treatment for NASH (2C). Pathologists are 
to be familiar with the histological characteristics of 
NAFLD in children (1B). 
 Individual biomarkers of NAFLD and 
NASH 
 The gold standard for NAFLD and NASH diagnoses is 
the liver biopsy in conjunction with the exclusion of 
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chronic alcohol consumption and other underlying dis-
eases (Table  3). Indirect evidence may arise from clinical 
signs and symptoms as well as findings of laboratory and 
imaging tests, and the combination thereof. Most clinical, 
laboratory and radiological tests are not sensitive and spe-
cific enough to differentiate between NAFLD and NASH and 
to determine the presence and extent of fibrosis  [26 – 28] . 
 Most patients with NAFLD are asymptomatic. If 
present at all, the symptoms and clinical findings are non-
specific. Components of the metabolic syndrome most com-
monly found are: overweight or obesity, diabetes and/or 
hypertension. 
 There is no single laboratory parameter that allows 
for the diagnosis of NAFLD or differentiates between stea-
tosis, NASH and fibrosis. Although elevated aminotrans-
ferase activities often point towards NAFLD, liver enzyme 
activities are normal in up to 78% of NAFLD patients. If 
at all. ALT and AST activities are moderately increased 
up to four times the upper limit of the reference range. 
In patients with little or no fibrosis, the ALT/AST ratio is 
typically  < 1; in the case of cirrhosis,  > 1. The activity of 
gamma-glutamyl transferase ( γ GT) is often increased in 
patients with NAFLD. Increased  γ GT is associated with 
fibrosis and increased mortality risk in NAFLD patients. 
Using a cut-off of 100 U/L, sensitivity and specificity are at 
approximately 80% and 70%, respectively  [26 – 28] . 
 In recent years, an increased apoptosis rate was dis-
covered to be a typical sign of NASH. This knowledge led 
to the discovery of fragments produced by the enzymatic 
cleavage of cytokeratin-18 (CK-18) by the caspases 3 and 
7, which are released into the plasma  [29] . Plasma levels 
of CK-18 fragments are increased in patients with NASH 
and enable their differentiation from steatosis. CK-18 frag-
ments are superior to other candidate biomarkers, such 
as the adipocyte fatty acid binding protein (FABP4) or 
the fibroblast growth factor 21 (FGF21), both in the differ-
entiation of NAFLD patients from controls (AUROC = 0.91 
compared to 0.66 or 0.84) as well as in the differentiation 
between steatosis and NASH (AUROC = 0.70 compared to 
0.59 or 0.62)  [30] . In several studies, CK-18 fragments had 
an AUROC of 0.80 – 0.93. At the optimal diagnostic cut-
offs, specificity was 81% – 100%, and sensitivity amounted 
to 62% – 82%. The biggest and only multicenter valida-
tion study to date revealed an AUROC of 0.83 (ALT, by 
comparison: 0.58), with a sensitivity of 75% and a speci-
ficity of 81% at the ideal cut-off  [31] . However, the com-
mercially available CK-18 fragment immunoassays differ 
in their specificity for caspase-cleaved CK-18, which may 
have led to considerable variation in the diagnostic effi-
ciency in the previous studies. A Hannover-based working 
group, therefore, compared the M30-ELISA in 121 NAFLD 
patients, which only recognizes caspase-cleaved CK-18 
fragments and thus measures liver cell apoptosis, with 
the M65-ELISA, which detects both cleaved and uncleaved 
CK-18 and thus measures cell death in total. Both in the 
differentiation between steatosis and NASH as well as in 
differentiating mild fibrosis degrees, the M65 ELISA per-
formed better than the M30-ELISA  [32] . 
 Biomarker panel and algorithms 
for diagnosis and stratification 
of NAFLD 
 In recent years, several algorithms and scores have been 
developed to diagnose NAFLD and NASH with simple 
laboratory parameters and clinical information and to 
categorize NASH by fibrosis stages. 
 The NAFLD liver fat score, the fatty liver index (FLI) 
and the hepatic steatosis index (HSI) were developed to 
identify patients with steatosis. The NAFLD liver fat score 
contains as variables the presence of the metabolic syn-
drome or type 2 diabetes mellitus, fasting insulin, AST as 
well as AST/ALT ratio and showed an AUROC of 0.86 – 0.87. 
The fatty liver index takes into account the body mass 
index (BMI), waist circumference, triglyceride levels, and 
thus generates a scale from 0 to 100. The AUROC was 0.84. 
The HSI integrates ALT, AST, BMI, age and sex and, in a 
cohort of over 5000 people, reached an AUROC of 0.81 
 [28] . 
 A whole range of scores and algorithms has been 
developed to diagnose NASH. Their average AUROCs 
amounted to 0.76. Some of these algorithms use simple 
information, such as the HAIR score (integrating  H yper-
tension,  A LT and  I nsulin  R esistance), or a clinical model 
that combines age, sex, BMI, AST, AST/ALT ratio and hya-
luronic acid. More complicated models, which partially 
require also less common laboratory parameters, such 
as the NashTest with 13 variables (age, sex, height and 
weight as well as the serum levels of triglycerides, choles-
terol,  α 2 macroglobulin, apolipoprotein AI, haptoglobin, 
 γ GT, ALT, AST, and total bilirubin), or a model developed 
by Younoussi et al. (diabetes, sex, BMI, triglycerides, CK-18 
fragments and total CK-18), did not produce any improved 
diagnostic performance either  [26, 28] . 
 For the detection and staging of fibrosis in NASH 
patients, algorithms were evaluated that were developed 
either for patients with chronic hepatitis C (FibroTest  ®  , 
Fibrometer  ®  , ELF, APRI) or specifically for NAFLD patients 
(NAFLD Fibrosis Score, BARD score)  [3, 26, 28] .  Table 5 
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summarizes the evaluated NAFLD scores. American gas-
troenterologists favor the NAFLD fibrosis score in their 
guidelines  [16] . In a meta-analysis, the NAFLD fibro-
sis score in the detection of NASH with advanced fibro-
sis (  ≥  F3) yielded an AUROC, sensitivity and specificity 
at the ideal cut-off of 0.85, 0.90 and 0.97  [33] . In a direct 
comparison, Fibrometer  ®  , in the detection of significant 
fibrosis ( > F2), produced an AUROC of 0.94 and was thus 
superior to the NAFLD fibrosis score (AUROC 0.88) and 
APRI (AUROC 0.87) favored by American gastroenterolo-
gists. There was no difference in the diagnosis of cirrhosis 
(AUROCs: 0.90, 0.90, 0.84)  [34] . In another comparative 
study  [35] , transient elastography, AST/ALT ratio, APRI, 
FIB-4, BARD and NAFLD fibrosis score were compared. 
As with chronic hepatitis, imaging was superior to all bio-
marker scores. For   ≥  F3 fibrosis, the AUROC of transient 
elastography was 0.93 compared to 0.66 (AST/ALT ratio) 
and 0.80 (FIB4) in the biomarkers. In connection with cir-
rhosis, the AUROCs were 0.95 for transient elastography 
and 0.62 (BARD) as well as 0.80 or 0.81 (NAFLD score or 
FIB-4, respectively) for the biomarkers. 
 In summary, there is unfortunately no single labora-
tory parameter that allows for the reliable diagnosis or 
staging of NAFLD or NASH. CK-18 is currently the most 
promising single parameter for the diagnosis of NASH. 
Accordingly, American gastroenterologists and hepatolo-
gists have emphasized CK-18 in their recommendations, 
but without calling for its routine use  [16] . Further valida-
tion studies are needed. CK-18 is currently not available 
as a routine test. The data situation regarding the sig-
nificance of scores and algorithms for the diagnosis and 
severity classification of NAFLD and NASH is not as reli-
ably secured or confirmed as is the significance of scores 
used in connection with chronic hepatitis. Nevertheless, 
the fibrosis scores seem well suited to estimate fibrosis in 
connection with NAFLD. Again, the patented scores seem 
superior to the freely available ones, including the NAFLD 
fibrosis scores favored in the guidelines. The latter, of 
course, are easily available. Scores created by conven-
tional markers also seem inferior to CK-18 in the diagnosis 
of NASH. 
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